130 322

Cited 0 times in

Effects of Pamidronate Treatment on Osteogenesis Imperfecta

DC Field Value Language
dc.contributor.author이, 승원-
dc.contributor.author김, 현주-
dc.contributor.author조, 재현-
dc.contributor.author이, 형숙-
dc.contributor.author정, 연무-
dc.contributor.author김, 대중-
dc.contributor.author이, 관우-
dc.contributor.author정, 윤석-
dc.date.accessioned2011-12-28T05:22:47Z-
dc.date.available2011-12-28T05:22:47Z-
dc.date.issued2004-
dc.identifier.issn1015-6380-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/5079-
dc.description.abstractBackground:Osteogenesis imperfecta (OI) is a congenital disorder of type I collagen, with variable phenotypes, due to increased bone fragility and low bone mass. Previous pharmacological treatments for OI have been attempted with calcitonin and growth hormone but with little beneficial effects. Recently, Glorieux reported the beneficial effects of bisphosphonates in OI.



Methods:In this study, the effects of pamidronate treatment were evaluated in 9 patients with OI. All patients received intravenous pamidronate infusions, which was dose adjusted according to the patients’ age. The outcome measures included the biochemical bone markers; serum alkaline phosphatase, urine deoxy-pyridinoline, urine Ca/Cr ratio, and bone mineral density (BMD).



Results:Serum alkaline phosphatase, urine deoxypyridinoline, and urine Ca/Cr ratio were slightly decreased after 1 year of therapy, although these changes were not statistically significant. The BMDs of the lumbar spine and proximal femur were significantly increased after 1-year of pamidronate treatment. No fractures were reported during the 1 year treatment periods.



Conclusions:Pamidronate treatment had an effect on the BMD in osteogenesis imperfecta, probably due to decreasing bone resorption
-
dc.language.isoko-
dc.titleEffects of Pamidronate Treatment on Osteogenesis Imperfecta-
dc.title.alternative골형성부전증 환자에서 파미드로네이트의 치료 효과-
dc.typeArticle-
dc.identifier.urlhttp://kmbase.medric.or.kr/Main.aspx?d=KMBASE&m=VIEW&i=0356620040190050485-
dc.subject.keywordOsteogenesis imperfecta-
dc.subject.keywordPamidronate-
dc.subject.keywordBiochemical bone marker-
dc.subject.keywordBone mineral density-
dc.type.localJournal Papers-
dc.citation.titleJournal of Korean Society of Endocrinology-
dc.citation.title대한내분비학회지-
dc.citation.volume19-
dc.citation.number5-
dc.citation.date2004-
dc.citation.startPage485-
dc.citation.endPage491-
dc.identifier.bibliographicCitationJournal of Korean Society of Endocrinology, 19(5):485-491, 2004-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Endocrinology & Metabolism
Files in This Item:
Journal of Korean Society of Endocrinology_19(5)_485-491.pdfDownload

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse